Skip to content

Treatment of Severe Heart Failure by Ultrafiltration

Ultrafiltration for the Chronic Treatment of Severe Congestive Heart Failure

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00360958
Enrollment
60
Registered
2006-08-07
Start date
2006-08-31
Completion date
2012-12-31
Last updated
2016-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Congestive Heart Failure

Keywords

ultrafiltration, heart failure, fluid overload

Brief summary

Patients with severe congestive heart failure show increased fluid body content which is often resistant to conventional diuretic therapy. Therefore, chronic heart failure patients have frequent access to the emergency room and hospital for hemodynamic instability. Ultrafiltration is a simple renal replacement therapy which reduces fluid overload. The purpose of this study is to determine whether periodic ultrafiltration sessions maintain patients in stable clinical condition and reduce hospitalisations as well as access to emergency heart failure treatment.

Detailed description

Patients with severe heart failure (New York Heart Association \[NYHA\] III-IV) and fluid overload will be randomized to ultrafiltration (UF group) or conventional medical treatment (Control group). Patients follow-up at least monthly visit for one year. Ultrafiltration will be repeated during follow-up in case of body weight gain due to fluid accumulation. Ultrafiltration will be performed during short term hospitalization.

Interventions

Sponsors

Centro Cardiologico Monzino
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Severe heart failure (NYHA III-IV) with fluid overload * Ejection fraction \< 40% * Estimated fluid overload \> 4 kg

Exclusion criteria

* Severe renal insufficiency * Acute pulmonary edema and/or cardiogenic shock

Design outcomes

Primary

MeasureTime frame
number of hospitalizations for heart failureEnd of study

Secondary

MeasureTime frame
long term major adverse clinical events including deathEnd of study

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026